Relmada halts depression drug trials, shifts focus to psilocybin program amid review

Green Market Report
By Adam JacksonDec 9, 2024, 9:11 am65 pts
Relmada Therapeutics Inc. (Nasdaq: RLMD) will halt its Phase 3 studies of depression treatment REL-1017 following a data monitoring committee evaluation, sending the company searching for strategic alternatives. The late-stage biotechnology company will discontinue both the Reliance II and Relight Phase 3…

Read Article Share
Share Article
- email
- twitter
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on NewsBudz

Federal Agency Honors Hemp Company With Award Recognizing Commitment To Veterans’ Employment 65

From Lacrosse to Cannabis: How Dave Morrow Built Michigan’s Largest Weed Empire 63

Deadly Mushrooms in Thailand: A Warning for America’s Psychedelic Experiment 61

Top Cannabis Strains for Cozy Winter Nights: Strains that pair well with winter vibes 60

Cannabis Stocks Perhaps Have Bottomed 59

About NewsBudz

NewsBudz is a marijuana and medical cannabis news app. The site delivers a daily feed of the latest cannabis news. We aggregate over 30 of the web's best sources for news about marijuana, hemp and legalization to keep you informed.

Stay on top of the latest news headlines, trends and developments worldwide around recreational and medical marijuana. Sit back and relax, while you read learn and share. On the web or your mobile device, NewsBudz is your cannabis news stream.